Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Caribou Biosciences (CRBU) Assets Average (2021 - 2025)

Caribou Biosciences (CRBU) has disclosed Assets Average for 5 consecutive years, with $247.3 million as the latest value for Q2 2025.

  • On a quarterly basis, Assets Average fell 36.58% to $247.3 million in Q2 2025 year-over-year; TTM through Jun 2025 was $247.3 million, a 36.58% decrease, with the full-year FY2024 number at $372.8 million, down 7.5% from a year prior.
  • Assets Average was $247.3 million for Q2 2025 at Caribou Biosciences, down from $293.5 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $452.2 million in Q4 2021 to a low of $247.3 million in Q2 2025.
  • A 5-year average of $381.7 million and a median of $396.7 million in 2023 define the central range for Assets Average.
  • Peak YoY movement for Assets Average: skyrocketed 32.21% in 2022, then tumbled 36.58% in 2025.
  • Caribou Biosciences' Assets Average stood at $452.2 million in 2021, then fell by 14.57% to $386.3 million in 2022, then rose by 15.16% to $444.9 million in 2023, then dropped by 12.36% to $389.9 million in 2024, then crashed by 36.58% to $247.3 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Assets Average are $247.3 million (Q2 2025), $293.5 million (Q1 2025), and $389.9 million (Q2 2024).